Systemic lupus erythematosus (SLE) is an autoimmune disorder of indeterminate etiology characterized by profound T cell effector dysfunction. The fundamental molecular mechanisms underlying T cell dysfunction remain largely unknown. Infection-related morbidity and mortality rates are high among patients with SLE and attributed to disease activity, the use of immunosuppressive drugs and deficient cell-mediated cytotoxic responses that are associated with decreased expression of interleukin-2 (IL-2). Besides the contribution to the increased rate of infections, decreased IL-2 production is involved in the defective activation-induced cell death that is important for the elimination of autoreactive T cells and the generation of T regulatory cells, which are believed to be decreased in SLE patients. Evidence suggests that the production of IL-2 is controlled at the gene transcription level. Specifically, it has been documented that SLE T cells have increased amounts of serine/threonine phosphatase 2A (PP2Ac) which limits the amounts of the phosphorylated (p) cAMP responsive element binding protein (CREB), a transcriptional enhancer. The increased expression of PP2Ac appears to be controlled at the transcriptional level through a CpG motif and single nucleotide polymprphisms (SNPs) located throughout the gene. In addition, certain regulatory B subunits of the PP2A trimolecular complex are aberrantly expressed in SLE T cells and account for specific T cell malfunction. Finally, a novel mouse over expressing PP2Ac in T cells produces increased amounts of IL-17 and is prone to glomerulonephritis. The hypothesis that PP2Ac represents a main contributor in the immunopathogenesis of SLE will be tested by determining genetic and epigenetic mechanisms that control the expression of PP2A in human SLE T cells;establishing the aberrant expression of B regulatory subunits in human SLE T cells and determining how each one of them contributes to a specific abnormal T cell function, and using the Cd2-Pp2ac mouse to establish the contribution of increased expression of PP2Ac in the autoimmune response and pathology. This line of research will generate novel information on the origin of T cell malfunction in SLE patients and will identify novel approaches to correct IL-2 production which will help decrease the rate of infections by restoring immune cell function.
Systemic lupus erythematosus (SLE) is an autoimmune disorder of indeterminate etiology characterized by profound T cell effector dysfunction. Infection-related morbidity and mortality rates are high among patients with SLE and it is attributed to disease activity, the use of immunosuppressive drugs and deficient cell- mediated cytotoxic responses that are associated with decreased expression of interleukin-2. Understanding the molecular mechanisms that account for the decreased production of interleukin-2 will generate novel information which will guide approaches to correct its production and help decrease the rate of infections by restoring immune cell function.
|Lo, Mindy S; Tsokos, George C (2018) Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy. Curr Opin Rheumatol 30:222-228|
|Sharabi, Amir; Kasper, Isaac R; Tsokos, George C (2018) The serine/threonine protein phosphatase 2A controls autoimmunity. Clin Immunol 186:38-42|
|Moulton, Vaishali R; Suarez-Fueyo, Abel; Meidan, Esra et al. (2017) Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. Trends Mol Med 23:615-635|
|Apostolidis, Sokratis A; Rodríguez-Rodríguez, Noé; Suárez-Fueyo, Abel et al. (2016) Phosphatase PP2A is requisite for the function of regulatory T cells. Nat Immunol 17:556-64|
|Kasper, Isaac R; Apostolidis, Sokratis A; Sharabi, Amir et al. (2016) Empowering Regulatory T Cells in Autoimmunity. Trends Mol Med 22:784-797|
|Moulton, Vaishali R; Tsokos, George C (2015) T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J Clin Invest 125:2220-7|
|Otomo, Kotaro; Koga, Tomohiro; Mizui, Masayuki et al. (2015) Cutting Edge: Nanogel-Based Delivery of an Inhibitor of CaMK4 to CD4+ T Cells Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice. J Immunol 195:5533-7|
|Nagpal, Kamalpreet; Watanabe, Katsue Sunahori; Tsao, Betty P et al. (2014) Transcription factor Ikaros represses protein phosphatase 2A (PP2A) expression through an intronic binding site. J Biol Chem 289:13751-7|
|Grammatikos, Alexandros P; Kyttaris, Vasileios C; Kis-Toth, Katalin et al. (2014) A T cell gene expression panel for the diagnosis and monitoring of disease activity in patients with systemic lupus erythematosus. Clin Immunol 150:192-200|
|Sunahori, Katsue; Nagpal, Kamalpreet; Hedrich, Christian M et al. (2013) The catalytic subunit of protein phosphatase 2A (PP2Ac) promotes DNA hypomethylation by suppressing the phosphorylated mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)/phosphorylated ERK/DNMT1 protein pathway in T- J Biol Chem 288:21936-44|
Showing the most recent 10 out of 24 publications